Clinicians across the United States are rationing the only long-acting penicillin approved for syphilis treatment after the manufacturer pushed its next delivery of Bicillin L-A to October 2026 and federal agencies projected the shortage would persist through the fourth quarter of 2027. The supply crisis, compounded by a July 2025 recall and rising syphilis rates, has forced the FDA to allow temporary imports of two foreign-made alternatives while state health departments scramble to prioritize doses for pregnant patients and newborns at risk of congenital syphilis.
Why the Bicillin L-A shortage is reshaping syphilis care right now
Benzathine penicillin G, sold in the U.S. as Bicillin L-A, is the only FDA-approved drug recommended for treating all stages of syphilis, including during pregnancy. No oral substitute exists. When the sole manufacturer extended its next anticipated delivery of both 1.2 MU and 2.4 MU prefilled syringes to October 2026, providers lost the one reliable pipeline for a drug that current syphilis guidance calls the standard of care. The same update placed full supply recovery in Q4 2027, meaning clinics will operate under constrained allocation for at least another 18 months.
That timeline creates a direct threat to patients. A July 2025 recall further reduced available stock, and CDC guidance issued in response urged providers to carefully stage doses and conserve remaining supply. Pregnant patients sit at the front of the line because untreated maternal syphilis can cause stillbirth, severe birth defects, and neonatal death. Every week of rationing increases the chance that someone who needs three weekly injections receives fewer, or none at all. In many jurisdictions, health departments now require justification for every non-pregnancy dose, effectively turning a once-routine prescription into a scarce, triaged intervention.
One hypothesis worth tracking is that states securing larger shares of the imported alternatives in 2026 should, in theory, record lower rates of syphilis treatment failure and retreatment by mid-2027 than states relying solely on the limited domestic allocation. No federal dataset currently tracks those state-level outcomes in real time, but the logic follows directly from the supply math. If imported doses fill the gap, treatment completion rates hold. If they do not, retreatment visits and congenital syphilis cases will climb, especially in regions already experiencing rapid increases in primary and secondary infections.
Federal import workarounds and the supply timeline
To bridge the gap, the FDA announced temporary importation of Lentocilin on March 6, 2026, a benzathine benzylpenicillin product not normally approved for U.S. sale. That step followed an earlier enforcement discretion decision allowing importation of Extencilline, a French-manufactured equivalent, as outlined in CDC information for product availability during the shortage. Both products contain the same active ingredient as Bicillin L-A but arrive in different packaging and labeling, requiring clinicians to adjust preparation and dosing workflows and to educate staff on new instructions for reconstitution and administration.
The FDA’s own shortage documentation, released as a detailed drug supply file, lists projections for Bicillin L-A prefilled syringes in three formulations: 1.2 MU, 2.4 MU, and pediatric doses. All three show the same October 2026 target for the next batch, with no guarantee of volume. Maine’s health department issued a public advisory stating that Bicillin L-A is the only U.S.-approved recommended therapy for syphilis and that the shortage is now expected to persist through Q4 2027. That advisory reflects what clinicians on the ground already know: even when October deliveries arrive, they will not restore normal supply levels, and health systems should plan for ongoing conservation measures.
The shortage is not confined to the United States. Australia’s Therapeutic Goods Administration extended its own Bicillin L-A shortage notice through November 30, 2026, with later updates pushing the timeline into 2027. The global nature of the disruption limits how much relief imported alternatives can provide, since the same manufacturing constraints affect supply chains in multiple countries simultaneously. When one country diverts stock to cover a domestic gap, it effectively reduces the pool available for others facing similar surges in syphilis.
For now, the imported products function as a stopgap rather than a solution. They arrive in intermittent shipments, often earmarked first for public-sector clinics that serve pregnant patients and infants. Private practices, sexual health clinics, and rural hospitals may receive only a fraction of what they request, if any. That patchwork distribution deepens geographic inequities in access to definitive therapy.
How rationing is changing front-line practice
On the front lines, rationing has reshaped how clinicians approach every positive syphilis test. Many health departments now require confirmation that a patient is not pregnant and does not have neurologic symptoms before authorizing a Bicillin L-A dose. Patients who fall outside those high-priority categories are increasingly steered toward alternative regimens, such as multi-dose oral therapies, even though those options are less convenient and may be less effective in certain stages of infection.
Clinicians also report longer counseling visits as they explain why some patients receive injections while others do not. In communities with high distrust of the medical system, those conversations can be fraught. Providers must balance transparency about the shortage with reassurance that alternative regimens, when taken correctly, still offer meaningful protection against long-term complications.
Meanwhile, contact tracing teams face a moving target. When supplies were stable, partners of newly diagnosed patients could be offered immediate, standardized treatment. Under rationing, public health workers must assess each partner’s pregnancy status, symptoms, and likelihood of follow-up before deciding who receives an injection and who is scheduled for an oral regimen. That added complexity slows response times just as caseloads are rising.
Gaps in tracking and what clinicians should watch next
Several critical questions remain unanswered. No primary CDC or FDA dataset quantifies how many patients have been turned away, switched to less effective regimens, or experienced treatment failure since the shortage intensified after the July 2025 recall. Without that data, public health officials cannot measure whether the imported alternatives are actually reaching the patients who need them most, or whether they are pooling in well-resourced urban centers while rural clinics go without. State-level surveillance for congenital syphilis offers one indirect indicator, but those figures lag behind real-time clinical decisions by months or years.
Comparative safety and efficacy data for Lentocilin and Extencilline in U.S. populations also do not exist in published form. Both products are widely used internationally, but neither has gone through the standard FDA approval process. Clinicians are administering them under enforcement discretion, a regulatory gray zone that works in an emergency but leaves gaps in pharmacovigilance reporting. Adverse event monitoring depends heavily on voluntary reporting, which may undercount milder reactions or events that clinicians attribute to syphilis itself rather than the injection.
The October 2026 delivery date is the next concrete marker. If that shipment arrives on schedule and in sufficient volume, providers will have their first meaningful domestic resupply in months, and some jurisdictions may cautiously expand eligibility beyond pregnant patients and infants. If it slips again, health departments will need to extend and possibly tighten rationing protocols, with renewed emphasis on alternative regimens and intensified outreach to patients at highest risk of being lost to follow-up.
In the meantime, clinicians can focus on several practical steps: documenting every instance in which Bicillin L-A is unavailable for a guideline-concordant indication, reporting adverse events associated with imported products, and collaborating with local health departments to refine prioritization criteria as new information emerges. Those granular data points, collected clinic by clinic, may ultimately provide the clearest picture of how a prolonged shortage of a single, irreplaceable drug reshaped the trajectory of syphilis in the United States.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
